Oncology and Hematology - Global Oncology Academy

Episodes 97-106 of 106

Significance of HER2 Expression in Solid Tumors
Significance of HER2 Expression in Solid Tumors
MinuteCE®
Significance of HER2 Expression in Solid Tumors
0.75 program credits
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 program credits
MinuteCE®
Expanding Horizons: HER2 Targeting in Metastatic Solid Tumors
0.75 credits 8 episodes
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 credits 8 episodes
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
MinuteCE®
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
MinuteCE®
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
0.75 program credits
- Shubham Pant, MD, MBBS
0.75 program credits
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
MinuteCE®
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
MinuteCE®
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
0.75 program credits
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 program credits
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
MinuteCE®
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
Myeloma Matters: Bispecific Antibody Horizons: Dosing Strategies and Meeting Updates in Myeloma Care
Myeloma Matters: Bispecific Antibody Horizons: Dosing Strategies and Meeting Updates in Myeloma Care
Project Oncology®
Myeloma Matters: Bispecific Antibody Horizons: Dosing Strategies and Meeting Updates in Myeloma Care
- Saad Z. Usmani, MD, MBA, FACP
- Joshua Richter, MD
- Ashley Steinberger, APP
Multiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings
Multiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings
CME/CE
Multiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings
0.25 credits
- Jennifer Caudle, DO
- Patricia A. Mangan, RN, MSN, APRN-BC
0.25 credits
Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma
Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma
Project Oncology®
Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma
- Jesus G. Berdeja, MD
- Nicholas G. Barkemeyer, MPAS
- Ajai Chari, MD
- Harvey Church
- Amy Gebhardt
- Steven Morrow

Previous
1
2
…
5
6
7
Next

7/6